

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7016928

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	THE FOUNDRY, LLC	12/05/2019
RECEIVING PARTY DATA		
Name:	FOUNDRY THERAPEUTICS, INC.	
Street Address:	4040 CAMPBELL AVE.	
Internal Address:	SUITE 110	
City:	MENLO PARK	
State/Country:	CALIFORNIA	
Postal Code:	94025	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17454320
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	docketing@fortemip.com	
Correspondent Name:	FORTEM IP LLP	
Address Line 1:	89 YESLER WAY	
Address Line 2:	SUITE 401	
Address Line 4:	SEATTLE, WASHINGTON 98104	
ATTORNEY DOCKET NUMBER:	FTX.001NPC2	
NAME OF SUBMITTER:	MICHAEL NAVARRO	
SIGNATURE:	/Michael Navarro/	
DATE SIGNED:	11/10/2021	
Total Attachments: 3		
source=2_Assignment-FOU-FTX_FTX001NPC2#page1.tif		
source=2_Assignment-FOU-FTX_FTX001NPC2#page2.tif		
source=2_Assignment-FOU-FTX_FTX001NPC2#page3.tif		

ASSIGNMENT

WHEREAS, The Foundry, LLC (hereinafter the "Assignor"), owns a right, title, and interest in and to any and all Inventions disclosed and/or claimed in the Applications for Letters Patent titled

IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS,
bearing PCT Patent Application No. PCT/US18/54777, filed on October 6, 2018,

DEVICES, SYSTEMS, AND METHODS FOR TREATING INTRALUMINAL CANCER VIA
CONTROLLED DELIVERY OF THERAPEUTIC AGENTS, bearing PCT Patent Application No.
PCT/US19/12795, filed January 8, 2019;

IMPLANTABLE DEPOTS FOR CONTROLLED RELEASE OF ANALGESICS TO TREAT
POSTOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND ASSOCIATED
DEVICES, SYSTEMS, AND METHODS, bearing PCT Patent Application No. PCT/US18/54779, filed
October 6, 2018,

IMPLANTABLE DEPOTS FOR CONTROLLED RELEASE OF ANALGESICS TO TREAT
POSTOPERATIVE PAIN, AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS, bearing PCT
Patent Application No. PCT/US18/54780, filed October 6, 2018, and

IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS, bearing
U.S. Provisional Patent Application No. 62/742,357, filed October 6, 2018,

WHEREAS,

Foundry Therapeutics, Inc.

a Delaware corporation having a place of business at 4040 Campbell Ave, Ste 110, Menlo Park, CA 94025 USA, (hereinafter the "Assignee"), desires to acquire the Assignor's right, title and interest in and to any and all said Inventions and any and all said Applications, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by the Assignor to have been received in full from the Assignee:

1. The Assignor does hereby sell, assign, transfer and convey unto the Assignee its right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Applications; (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Applications; (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; and (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for the Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. The Assignor hereby covenants and agrees to cooperate with the Assignee to enable the Assignee to

Assignment

App. Nos.: PCT/US18/54777, PCT/US19/12795, PCT/US18/54779, PCT/US18/54780, and 62/742,357

Docket Nos.: FTX.001WO, FTX.002WO, FTX.003WO, FTX.004WO, and FTX.005P

enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in the Assignee the right, title and interest herein conveyed; (b) for prosecuting any and all of said Applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limit on reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. The Assignor hereby warrants, represents and covenants that the Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. The Assignor hereby requests that any Patent in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of the Assignee, its successors, legal representatives and assigns.

6. The Assignor authorizes said Assignee and/or any legal representative of the Assignee to modify this Assignment solely to include any identifying information for any and all said Applications, including patent application number and patent application filing date.

7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, the Assignor has executed and delivered this instrument to the Assignee as of the date written below.

[SIGNATURE PAGES FOLLOW]


Assignment

App. Nos.: PCT/US18/54777, PCT/US19/12795, PCT/US18/54779, PCT/US18/54780, and 62/742,357

Docket Nos.: FTX.001WO, FTX.002WO, FTX.003WO, FTX.004WO, and FTX.005P

ASSIGNOR: The Foundry, LLC

DocuSigned by:



Date: 0516287F3AD408...


By: 12/5/2019

Name: Kara Liebig

Title: Partner

RECEIVED AND AGREED TO BY ASSIGNEE: Foundry Therapeutics, Inc.

DocuSigned by:



Date: 04DB49F312459...

By: 12/5/2019

Name: Hanson S. Gifford, III

Title: CEO